|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MOUNTAIN VIEW, Calif. and BARCELONA, Spain, June 21, 2016 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (OTC: ALXA, "Alexza") and Grupo Ferrer Internacional, S.A. ("Ferrer") today announced ...
Click here to see latest analysisAlexza Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Alexza Pharmaceuticals, Inc. – DURECT Corporation, Aradigm Corporation, BioDelivery Sciences International, Inc., Titan Pharmaceuticals, Inc., Paratek Pharmaceuticals Inc, Vanda Pharmaceuticals Inc., Nektar Therapeutics, Teva Pharmaceutical Industries Limited Sponsored […] (Read more...) The post Alexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 appeared first on CapitalCube.
NEW YORK, NY / ACCESSWIRE / May 13, 2016 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) stock ...